BCYC - Bicycle Therapeutics: Trying To Catch This Falling Knife

• Bicycle reported updated interim data from their lead cancer program, BT8009. Preliminary data suggestive of it being effective against solid tumors.
• Patients in the 5.0mg/m2 weekly BT8009 cohort showed a 50% overall response rate with favorable tolerability.
• The market’s initial reaction to the data was positive, however, the stock sold off in the subsequent trading days. I believe the market recognized the data from the other cohorts.
• The stock has dropped around 50% over the past week and has turned into a “Falling Knife”. I am contemplating trying to “catch the falling knife”. I discuss my strategy.
• BCYC is speculative, therefore, the ticker would be put into Compounding Healthcare's "Bio Boom" portfolio.

For further details see: